Benlysta® (belimumab) (Intravenous)

I. Length of Authorization

Coverage will be provided for 12 months and may be renewed.

II. Dosing Limits

A. Quantity Limit (max daily dose) [NDC Unit]:

   • Loading Dose (doses administered on days 1, 15 and 29):
     - Benlysta 120 mg SDV for injection: 9 vials per 29 days
     - Benlysta 400 mg SDV for injection: 9 vials per 29 days

   • Maintenance Dose:
     - Benlysta 120 mg SDV for injection: 3 vials per 28 days
     - Benlysta 400 mg SDV for injection: 3 vials per 28 days

B. Max Units (per dose and over time) [HCPCS Unit]:

   • Loading Dose (doses administered on days 1, 15 and 29):
     - 360 billable units per 29 days

   • Maintenance Dose:
     - 120 billable units per 28 days

III. Initial Approval Criteria

1. Patient is at least 18 years of age (unless otherwise specified): AND

Universal Criteria

1. Patient must not have an active infection: AND

2. Patient has not received a live vaccine within 30 days before starting or concurrently with Benlysta: AND

3. Will be used in combination with standard therapy (e.g., anti-malarials, corticosteroids, non-steroidal anti-inflammatory drugs, immunosuppressives): AND
• Patient does not have any of the following exclusion criteria:
  − Severe active central nervous system lupus
  − Individuals who are on other biologics: AND

**Systemic Lupus Erythematosus (SLE) †,3,4,9,11,18-15**

• Patient is at least 5 years of age: AND
• Patient has a confirmed diagnosis of SLE with at least 4 diagnostic features (see list of diagnostic SLE criteria below)* one of which must include a positive autoantibody test (e.g., anti-nuclear antibody [ANA] greater than laboratory reference range and/or anti-double-stranded DNA [anti-dsDNA] greater than 2 fold the laboratory reference range if tested by ELISA): AND
• Patient has failed to respond adequately to at least two (2) standard therapies such as anti-malarials, corticosteroids, non-steroidal anti-inflammatory drugs, immunosuppressives (excluding intravenous cyclophosphamide): AND
• Patient has one of the following:
  − Safety of Estrogen in Lupus National Assessment – Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score of 6-12
  − ≥2 British Isles Lupus Assessment Group (BILAG) B organ domain scores

**Lupus Nephritis 1,11,12,18-20**

• Patient has active lupus nephritis Class III, IV, or V as confirmed by renal biopsy: AND
• Patient has a confirmed diagnosis of SLE with at least 4 diagnostic features (see list of diagnostic SLE criteria below)* one of which must include a positive autoantibody test (e.g., anti-nuclear antibody [ANA] greater than laboratory reference range and/or anti-double-stranded DNA [anti-dsDNA] greater than 2 fold the laboratory reference range if tested by ELISA): AND
• Patient has failed to respond adequately to standard therapies including corticosteroids AND either cyclophosphamide or mycophenolate mofetil: AND
• Baseline measurement of one or more of the following: urine protein:creatinine ratio (uPCR), estimated glomerular filtration rate (eGFR), or urine protein

† FDA Approved Indication(s)

<table>
<thead>
<tr>
<th>*Systemic Lupus Erythematosus Diagnostic Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patient must have at least 4 out of 11 diagnostic SLE features:</strong></td>
</tr>
<tr>
<td>1. Malar rash</td>
</tr>
<tr>
<td>2. Discoid rash</td>
</tr>
<tr>
<td>3. Photosensitivity</td>
</tr>
<tr>
<td>4. Oral ulcers</td>
</tr>
<tr>
<td>5. Nonerosive arthritis (involving 2 or more peripheral joints)</td>
</tr>
<tr>
<td>6. Pleuritis/pericarditis</td>
</tr>
<tr>
<td>• Pleuritis - history of pleuritic pain or rubbing heard by a physician or evidence of pleural effusion</td>
</tr>
</tbody>
</table>
• Pericarditis - documented by electrocardiogram or rubbing heard by a physician or evidence of pericardial effusion
7. Renal disorder
• Persistent proteinuria > 0.5 grams/day or > 3+ on urine dipstick
• Cellular casts (red cell, hemoglobin, granular, tubular, or mixed)
8. Seizures/psychosis
9. Hematologic disorder
• Hemolytic anemia with reticulocytosis
• Leukopenia < 4,000/mm³ on ≥ 2 occasions
• Lymphopenia < 1,500/mm³ on ≥ 2 occasions
• Thrombocytopenia < 100,000/mm³ in the absence of offending drugs
10. Immunologic disorder
• Presence of anti-Sm or antiphospholipid antibodies
• Presence of anti-double-stranded DNA [anti-dsDNA] greater than 2 fold the laboratory reference range if tested by ELISA
11. Positive anti-nuclear antibody [ANA] greater than laboratory reference range

IV. Renewal Criteria

Coverage can be renewed based on the following criteria:

• Patient continues to meet universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III: AND
• Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include the following: depression, suicidal thoughts, serious infections, signs or symptoms of progressive multifocal leukoencephalopathy (PML), malignancy, severe hypersensitivity reactions/anaphylaxis, serious infusion reactions, etc.: AND

Systemic Lupus Erythematosus (SLE) 1,3,4,7,13-15
• Adequate documentation of disease stability and/or improvement as indicated by one or more of the following when compared to pre-treatment baseline:
  − Improvement in the SELENA-SLEDAI score of ≥4 points; OR
  − No new BILAG-A organ domain score or 2 new BILAG-B organ domain scores; OR
  − No worsening (<0.30-point increase) in Physician’s Global Assessment (PGA) score; OR
  − Seroconverted (negative)

Lupus Nephritis 1,19
• Adequate documentation of disease stability and/or improvement as indicated by one or more of the following when compared to pre-treatment baseline:
  − Urine protein:creatinine ratio (uPCR); OR
  − Estimated glomerular filtration rate (eGFR); OR
  − Urine protein

V. Dosage/Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dose</th>
</tr>
</thead>
</table>
Systemic lupus erythematosus (SLE) or Lupus Nephritis

- Loading Dose: 10 mg/kg intravenously (by a healthcare provider) every 2 weeks x 3 doses (days 1, 15 and 29)
- Maintenance Dose: 10 mg/kg intravenously (by a healthcare provider) every 4 weeks

VI. Billing Code/Availability Information

HCPCS Code:
- J0490 – Injection, belimumab, 10 mg; 1 billable unit = 10 mg

NDC:
- Benlysta 120 mg/5 mL SDV for injection: 49401-0101-xx
- Benlysta 400 mg/20 mL SDV for injection: 49401-0102-xx

VII. References


### Appendix 1 – Covered Diagnosis Codes

<table>
<thead>
<tr>
<th>ICD-10</th>
<th>ICD-10 Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>M32.10</td>
<td>Systemic lupus erythematosus organ or system involvement unspecified</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>------------------------------------------------------------</td>
</tr>
<tr>
<td>M32.11</td>
<td>Endocarditis in systemic lupus erythematosus</td>
</tr>
<tr>
<td>M32.12</td>
<td>Pericarditis in systemic lupus erythematosus</td>
</tr>
<tr>
<td>M32.13</td>
<td>Lung involvement in systemic lupus erythematosus</td>
</tr>
<tr>
<td>M32.14</td>
<td>Glomerular disease in systemic lupus erythematosus</td>
</tr>
<tr>
<td>M32.15</td>
<td>Tubulo-interstitial nephropathy in systemic lupus erythematosus</td>
</tr>
<tr>
<td>M32.19</td>
<td>Other organ or system involvement in systemic lupus erythematosus</td>
</tr>
<tr>
<td>M32.8</td>
<td>Other forms of systemic lupus erythematosus</td>
</tr>
<tr>
<td>M32.9</td>
<td>Systemic lupus erythematosus, unspecified</td>
</tr>
</tbody>
</table>

**Appendix 2 – Centers for Medicare and Medicaid Services (CMS)**

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) may exist and compliance with these policies is required where applicable. They can be found at: [http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx](http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx). Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

<table>
<thead>
<tr>
<th>Jurisdiction</th>
<th>Applicable State/US Territory</th>
<th>Contractor</th>
</tr>
</thead>
<tbody>
<tr>
<td>E (1)</td>
<td>CA, HI, NV, AS, GU, CNMI</td>
<td>Noridian Healthcare Solutions, LLC</td>
</tr>
<tr>
<td>F (2 &amp; 3)</td>
<td>AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ</td>
<td>Noridian Healthcare Solutions, LLC</td>
</tr>
<tr>
<td>5</td>
<td>KS, NE, IA, MO</td>
<td>Wisconsin Physicians Service Insurance Corp (WPS)</td>
</tr>
<tr>
<td>6</td>
<td>MN, WI, IL</td>
<td>National Government Services, Inc. (NGS)</td>
</tr>
<tr>
<td>H (4 &amp; 7)</td>
<td>LA, AR, MS, TX, OK, CO, NM</td>
<td>Novitas Solutions, Inc.</td>
</tr>
<tr>
<td>8</td>
<td>MI, IN</td>
<td>Wisconsin Physicians Service Insurance Corp (WPS)</td>
</tr>
<tr>
<td>N (9)</td>
<td>FL, PR, VI</td>
<td>First Coast Service Options, Inc.</td>
</tr>
<tr>
<td>J (10)</td>
<td>TN, GA, AL</td>
<td>Palmetto GBA, LLC</td>
</tr>
<tr>
<td>M (11)</td>
<td>NC, SC, WV, VA (excluding below)</td>
<td>Palmetto GBA, LLC</td>
</tr>
<tr>
<td>L (12)</td>
<td>DE, MD, PA, NJ, DC (includes Arlington &amp; Fairfax counties and the city of Alexandria in VA)</td>
<td>Novitas Solutions, Inc.</td>
</tr>
<tr>
<td>K (13 &amp; 14)</td>
<td>NY, CT, MA, RI, VT, ME, NH</td>
<td>National Government Services, Inc. (NGS)</td>
</tr>
<tr>
<td>15</td>
<td>KY, OH</td>
<td>CGS Administrators, LLC</td>
</tr>
</tbody>
</table>